1. US Food and Drug Administration, Center for Drug Evaluation and Research (CDER): Statistical procedures for bioequivalence studies using a standard two-treatment crossover design. Statement under 21 CFR 10.90, 29 June 1992.
2. Commission on the European Communities, CPMP Working Party on Efficacy of Medicinal Products, Note for Guidance, Investigation of Bioavailability and Bioequivalence, December 1991, III/54/89-EN.
3. US Food and Drug Administration, Center for Drug Evaluation and Research (CDER): Draft Guidance. In Vivo Bioequivalence Studies Based on Population and Individual Bioequivalence Approaches. October 1997.
4. On population and individual bioequivalence;Schall;Stat. Med.,1993
5. US Food and Drug Administration, Center for Drug Evaluation and Research (CDER): Draft Guidance. Average, Population, and Individual Approaches to Establishing Bioequivalence. August 1999.